2013年

November 19, 2013: Release of Flutiform, a combination drug for asthma treatment
November 5, 2013: Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2013)　[Japanese Standard]
October 17, 2013: Kyorin and Kissei announce the initiation of a Phase I clinical trial of KRP-EPA605/ KEA-0447 for the treatment of overactive bladder
September 20, 2013: Approval received for Flutiform, a combination drug for asthma treatment
July 30, 2013: Consolidated Financial Results (For the First Quarter Ended June 30,2013)- Supplementary Information
July 30, 2013: Summary of Consolidated Financial Results (For the First Quarter Ended June 30,2013)［Japanese Standard］
May 9, 2013: Summary of Consolidated Financial Results(For the fiscal year ended March 31, 2013)
May 9, 2013: Financial Results for the Fiscal 2012, the Year Ended March 31, 2013- Supplementary Information
March 25, 2013: Approval Received for PENTASA® Suppositories 1g,a Drug for Ulcerative colitis.
February 4, 2013: Consolidated Financial Results (For the Third Quarter Ended December 31,2012)- Supplementary Information
February 4, 2013: Summary of Consolidated Financial Results (For the Third Quarter Ended December 31,2012)［Japanese Standard］